RT Journal Article
SR Electronic
T1 Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.02.21258076
DO 10.1101/2021.06.02.21258076
A1 Dhar, Mahesh S
A1 Marwal, Robin
A1 Radhakrishnan, VS
A1 Ponnusamy, Kalaiarasan
A1 Jolly, Bani
A1 Bhoyar, Rahul C.
A1 Fatihi, Saman
A1 Datta, Meena
A1 Singh, Priyanka
A1 Sharma, Uma
A1 Ujjainia, Rajat
A1 Naushin, Salwa
A1 Bhateja, Nitin
A1 Divakar, Mohit Kumar
A1 Sardana, Viren
A1 Singh, Manoj K
A1 Imran, Mohamed
A1 Senthivel, Vigneshwar
A1 Maurya, Ranjeet
A1 Jha, Neha
A1 Mehta, Priyanka
A1 Rophina, Mercy
A1 Arvinden, VR
A1 Chaudhary, Urmila
A1 Thukral, Lipi
A1 Pandey, Rajesh
A1 Dash, Debasis
A1 Faruq, Mohammed
A1 Lall, Hemlata
A1 Gogia, Hema
A1 Madan, Preeti
A1 Kulkarni, Sanket
A1 Chauhan, Himanshu
A1 Sengupta, Shantanu
A1 Kabra, Sandhya
A1 ,
A1 Singh, Sujeet K
A1 Agrawal, Anurag
A1 Rakshit, Partha
YR 2021
UL http://medrxiv.org/content/early/2021/06/03/2021.06.02.21258076.abstract
AB In April 2021, after successfully enduring three waves of the SARS-CoV2 pandemic in 2020, and having reached population seropositivity of about 50%, Delhi, the national capital of India was overwhelmed by the fourth wave. Here, we trace viral, host, and social factors contributing to the scale and exponent of the fourth wave, when compared to preceding waves, in an epidemiological context. Genomic surveillance data from Delhi and surrounding states shows an early phase of the upsurge driven by the entry of the more transmissible B.1.1.7 variant of concern (VOC) into the region in January, with at least one B.1.1.7 super spreader event in February 2021, relatable to known mass gatherings over this period. This was followed by seeding of the B.1.617 VOC, which too is highly transmissible, with rapid expansion of B.1.617.2 sub-lineage outpacing all other lineages. This unprecedented growth of cases occurred in the background of high seropositivity, but with low median neutralizing antibody levels, in a serially sampled cohort. Vaccination breakthrough cases over this period were noted, disproportionately related to VOC in sequenced cases, but usually mild. We find that this surge of SARS-CoV2 infections in Delhi is best explained by the introduction of a new highly transmissible VOC, B.1.617.2, with likely immune-evasion properties; insufficient neutralizing immunity, despite high seropositivity; and social behavior that promoted transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupport from Ministry of Health and Family Welfare, Council of Scientific and Industrial Research, and Department of Biotechnology, India, is acknowledged.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SARSCoV2 genomic study was approved by the NCDC Ethics Review Committee vide approval 2020/NERC/14. The serology study was approved by the Institutional Human Ethics Committee of CSIRIGIB vide approval CSIR IGIB/IHEC/2019_20 All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data is being continuously uploaded on the GISAID. https://www.gisaid.org/